ARA290 demonstrates long-term relief from allodynia primarily through the activation of the β-common receptor, and its effectiveness in alleviating neuropathic pain is thought to stem from its anti-inflammatory properties, particularly within the central nervous system. Unlike erythropoietin, ARA290 lacks hematopoietic and cardiovascular side effects, making it a promising candidate for the prevention of neuropathic pain induced by peripheral nerve injuries in humans.
